BioSpace News Archive

Evoke Pharma, Inc. (NASDAQ: EVOK), today announced the start of additional marketing initiatives focusing on the launch of a patient and physician experience program for GIMOTI, the Company’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis (DGP).

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, July 28 , at 4:30 p.m. ET to discuss second quarter 2021 financial results and provide a general business update.

City of Hope and Osel, Inc. today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use of a LBP CBM588 to enhance efficacy of checkpoint inhibitors to treat cancer, including metastatic renal cell carcinoma.

Enable Biosciences is partnering with the California Department of Public Health (CDPH) in a statewide serosurvey program.

It’s hard to imagine losing your ability to have children when you’re only 30-years-old. But for women who suffer from uterine fibroids, that could be the reality if their doctor recommends they undergo a hysterectomy.

Kepley BioSystems received NSF funding to develop a disruptive innovation and global healthcare solution to combat sepsis.

CohBar, Inc. today announced an update on the timing for the release of the data for its Phase 1a/1b clinical study of CB4211 for the potential treatment of nonalcoholic steatohepatitis and obesity.

INmune Bio, Inc. today announced that it has entered into a definitive agreement with one healthcare focused institutional investor and one family office for the purchase and sale of 1,818,182 shares of its common stock at a price of $22.00 per share.

Escient Pharmaceuticals today announced positive results from a Phase 1 study of EP547, a new chemical entity and potent MrgprX4 antagonist, being developed for the treatment of pruritus associated with cholestasis and uremia.

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) today commended California Governor Gavin Newsom for signing the state’s FY 2021-2022 budget that includes $8.4 million to fund the California Parkinson’s Disease Registry (CPDR) and to expand it to other neurodegenerative diseases over the next four years.